Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea

Archives of Internal Medicine

Volumn 166, Issue 10, 2006, Pages 1081-1087

  Mueller, Christian ^a   Laule Kilian, Kirsten ^a   Schindler, Christian ^b   Klima, Theresia ^a   Frana, Barbara ^a   Rodriguez, Daniel ^a   Scholer, André ^a   Christ, Michael ^a   Perruchoud, André P ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; BRONCHODILATING AGENT; CORTICOSTEROID; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLYCERYL TRINITRATE; HYPERTENSIVE AGENT; INSULIN; LOOP DIURETIC AGENT;

ACUTE DISEASE; ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DYSPNEA; EMERGENCY WARD; FEMALE; FOLLOW UP; HEALTH CARE COST; HOSPITAL ADMISSION; HOSPITAL CHARGE; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION;

ACUTE DISEASE; AGED; COST-BENEFIT ANALYSIS; DIAGNOSIS, DIFFERENTIAL; DYSPNEA; FEMALE; FLUOROIMMUNOASSAY; HUMANS; LENGTH OF STAY; MALE; NATRIURETIC PEPTIDE, BRAIN; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD;

EID: 33646793595     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.166.10.1081     Document Type: Article

References (35)

1. Hunt SA, Baker DW, Chin MH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure); International Society for Heart and Lung Transplantation; Heart Failure Society of America. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Circulation. 2001;104:2996-3007.
2. Remme WJ, Swedberg K; Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 2001;22:1527-1560.
3. American Heart Association. Heart Disease and Stroke Statistics - 2003 Update. Dallas, Tex: American Heart Association; 2002.
4. Bhalla V, Willis S, Maisel AS. B-type natriuretic peptide: the level and the drug - partner in the diagnosis and management of congestive heart failure. Congest Heart Fail. 2004;10(suppl 1):3-27.
5. Maisel AS, Krishnaswamy P, Nowak RM, et al; Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161-167.
6. McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation. 2002;106:416-422.
7. Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans: evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest. 1991;87:1402-1412.
8. Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994;90:195-203.
9. Davis M, Espiner E, Richards G, et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet. 1994;343:440-444.
10. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet. 1998;351:9-13.
11. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004;350:647-654.
12. Mueller C, Buser P. B-type natriuretic peptide (BNP): can it improve our management of patients with congestive heart failure? Swiss Med Wkly. 2002;132:618-622.
13. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996;276:1253-1258.
14. Siegel JE, Weinstein MC, Russell LB, Gold MR; Panel on Cost-effectiveness in Heath and Medicine. Recommendations for reporting cost-effectiveness analysis. JAMA. 1996;276:1339-1341.
15. Briggs A, Fenn P. Confidence intervals or surfaces? uncertainty on the cost-effectiveness plane. Health Econ. 1998;7:723-740.
16. Black WC. The CE plane: a graphic representation of cost-effectiveness. Med Decis Making. 1990;10:212-214.
17. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ. 1997;6:327-340.
18. Glick H, Briggs AH, Polsky D. Quantifying stochastic uncertainty and presenting results of cost-effectiveness analyses. Expert Rev Pharmacoeconomics Outcomes Res. 2001;1:25-36.
19. Kaiser C, Brunner-La Rocca HP, Buser PT, et al; BASKET Investigators. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomized Basel Stent Kosten Effektivitäts Trial (BASKET). Lancet. 2005;366:921-929.
20. McCullough PA, Duc P, Omland T, et al; Breathing Not Properly Multinational Study Investigators. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis. 2003;41:571-579.
21. Hilleman DE, Dewan N, Malesker M, Friedman M. Pharmacoeconomic evaluation of COPD. Chest. 2000;118:1278-1285.
22. Packer M. Should B-type natriuretic peptide be measured routinely to guide the diagnosis and management of chronic heart failure? Circulation. 2003;108:2950-2953.
23. Tang WH, Girod JP, Lee MJ, et al. Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. Circulation. 2003;108:2964-2966.
24. Schwam E. B-type natriuretic peptide for diagnosis of heart failure in emergency department patients: a critical appraisal. Acad Emerg Med. 2004;11:686-691.
25. Wright SP, Doughty RN, Pearl A, et al. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. J Am Coll Cardiol. 2003;42:1793-1800.
26. Abraham WT, Adams KF, Fonarow GC, et al; ADHERE Scientific Advisory Committee and Investigators; ADHERE Study Group. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol. 2005;46:57-64.
27. Kelly J, Rudd A, Lewis RR, Hunt BJ. Plasma D-dimers in the diagnosis of venous thromboembolism. Arch Intern Med. 2002;162:747-756.
28. Ellison L, Cheli CD, Bright S, Veltri RW, Partin AW. Cost-benefit analysis of total, free/total, and complexed prostate-specific antigen for prostate cancer screening. Urology. 2002;60:42-46.
29. Nichol G, Kaul P, Huszti E, Bridges JF. Cost-effectiveness of cardiac resynchronization therapy in patients with symptomatic heart failure. Ann Intern Med. 2004;141:343-351.
30. Nielsen OW, McDonagh TA, Robb SD, Dargie HJ. Retrospective analysis of the cost-effectiveness of using plasma natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. J Am Coll Cardiol. 2003;41:113-120.
31. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355:1126-1130.
32. Richards AM, Doughty R, Nicholls MG, et al; Australia-New Zealand Heart Failure Group. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Circulation. 1999;99:786-792.
33. Mueller C, Laule-Kilian K, Scholer A, et al. B-type natriuretic peptide for acute dyspnea in patients with kidney disease: insights from a randomized comparison. Kidney Int. 2005;67:278-284.
34. Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004;109:594-600.
35. McCord J, Mundy BJ, Hudson MP, et al; Breathing Not Properly Multinational Study Investigators. Relationship between obesity and B-type natriuretic peptide levels. Arch Intern Med. 2004;164:2247-2252.